Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.67 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.58 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.56 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.56 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.56 |
| ▸ | MME | P08473 | 3/20 | 0.56 |
| ▸ | ACE | P12821 | 3/20 | 0.56 |
| ▸ | CPA1 | P15085 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7904964 | 1.00 | CA2 (0.69) | CA2ITGB1ITGA4PTPN1CA1 | |
| SCHEMBL8510030 | 0.93 | PTPN1 (0.70) | CA2ITGB1ITGA4PTPN1CA1 | |
| SCHEMBL1305154 | 0.93 | PTPN1 (0.70) | CA2ITGB1ITGA4PTPN1CA1 | |
| SCHEMBL2632872 | 0.90 | PTPN1 (0.74) | CA2ITGB1ITGA4PTPN1CA1 | |
| SCHEMBL8196220 | 0.90 | PTPN1 (0.74) | CA2ITGB1ITGA4PTPN1CA1 | |
| SCHEMBL10033681 | 0.90 | PTPN1 (0.69) | CA2ITGB1ITGA4PTPN1CA1 | |
| SCHEMBL6857183 | 0.90 | PTPN1 (0.69) | CA2ITGB1ITGA4PTPN1CA1 | |
| SCHEMBL5927385 | 0.89 | CA2 (0.62) | CA2ITGB1ITGA4PTPN1L3MBTL1 | |
| SCHEMBL4359915 | 0.88 | CTSL (0.64) | CA2PTPN1CA1CTSBCTSS | |
| SCHEMBL27679107 | 0.88 | CTSL (0.64) | CA2PTPN1CA1CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181175-B2 | Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid | Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181175-B2 | Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid | Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) | 2015-11-10 | — | — | US | disclosed |
| EP-2387558-B1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2014-08-27 | — | — | EP | disclosed |
| US-20140179947-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2014-06-26 | — | — | US | disclosed |
| US-20140179947-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2014-06-26 | — | — | US | disclosed |
| US-20120016151-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120016151-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2010081410-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179947-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | DNPEP, MME, DPP7 | CA2 1147/4885ITGB1 4491/4885ITGA4 4271/4885 |
| US-20120016151-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | DNPEP, MME, DPP7 | CA2 1147/4885ITGB1 4491/4885ITGA4 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.